Prognostic values of human epididymis protein 4 expression in patients with endometrial cancer: A systematic review and meta‐analysis

Han, Li-Na; Han, Yijie; Yan, Ping

doi:10.1111/jog.15356

Cited by 6 publications

(5 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar findings were presented by Han Li-Na et al [23], who conducted a meta-analysis assessing the link between HE4 and prognosis in EC. Their conclusion was that the HE4 marker may be a better predictor of EC than CA125, and high serum levels of HE4 were associated with poor OS and disease-free survival [23].…”

Section: Ca125 and Its Combinations With Other Parameters; Algorithms...supporting

confidence: 86%

“…A metaanalysis carried out by Li J et al [22] indicated that when histologic type and stage are not considered, the serum HE4 assay is a superior diagnostic tool for EC because of its increased sensitivity compared to the CA125 assay [22]. Similar findings were presented by Han Li-Na et al [23], who conducted a meta-analysis assessing the link between HE4 and prognosis in EC. Their conclusion was that the HE4 marker may be a better predictor of EC than CA125, and high serum levels of HE4 were associated with poor OS and disease-free survival [23].…”

Section: Ca125 and Its Combinations With Other Parameters; Algorithms...mentioning

confidence: 64%

See 1 more Smart Citation

Sensitivity and Specificity of Selected Biomarkers and Their Combinations in the Diagnosis of Ovarian Cancer

Englisz,

Smycz-Kubańska,

Mielczarek-Palacz

2024

Diagnostics

View full text Add to dashboard Cite

One of the greatest challenges in modern gynecological oncology is ovarian cancer. Despite the numerous studies currently being conducted, it is still sometimes detected at late clinical stages, where the prognosis is unfavorable. One significant contributing factor is the absence of sensitive and specific parameters that could aid in early diagnosis. An ideal screening test, in view of the low incidence of ovarian cancer, should have a sensitivity of greater than 75% and a specificity of at least 99.6%. To enhance sensitivity and specificity, diagnostic panels are being created by combining individual markers. The drive to develop better screening tests for ovarian cancer focuses on modern diagnostic methods based on molecular testing, which in turn aims to find increasingly effective biomarkers. Currently, researchers’ efforts are focused on the search for a complementary parameter to those most commonly used that would satisfactorily enhance the sensitivity and specificity of assays. Several biomarkers, including microRNA molecules, autoantibodies, cDNA, adipocytokines, and galectins, are currently being investigated by researchers. This article reviews recent studies comparing the sensitivity and specificity of selected parameters used alone and in combination to increase detection of ovarian cancer at an early stage.

show abstract

Section: Ca125 and Its Combinations With Other Parameters; Algorithms...supporting

confidence: 86%

Section: Ca125 and Its Combinations With Other Parameters; Algorithms...mentioning

confidence: 64%

Sensitivity and Specificity of Selected Biomarkers and Their Combinations in the Diagnosis of Ovarian Cancer

Englisz,

Smycz-Kubańska,

Mielczarek-Palacz

2024

Diagnostics

View full text Add to dashboard Cite

show abstract

“…HE4 was shown to have a higher sensitivity in patients with early-stage disease [30]. Han L. N. et al [31] conducted a meta-analysis of 38 published studies evaluating the association between HE4 and prognosis in endometrial cancer (EC). They found that high serum HE4 levels were associated with FIGO stages III-IV as well as with poor overall survival and disease-free survival.…”

Section: He4mentioning

confidence: 99%

“…They found that high serum HE4 levels were associated with FIGO stages III-IV as well as with poor overall survival and disease-free survival. Therefore, when compared with CA125, the serum HE4 marker may be a better prognostic indicator for EC [31].…”

Section: He4mentioning

confidence: 99%

Evaluation of the Potential Diagnostic Utility of the Determination of Selected Immunological and Molecular Parameters in Patients with Ovarian Cancer

2023

View full text Add to dashboard Cite

Ovarian cancer is one of the most serious challenges in modern gynaecological oncology. Due to its non-specific symptoms and the lack of an effective screening procedure to detect the disease at an early stage, ovarian cancer is still marked by a high mortality rate among women. For this reason, a great deal of research is being carried out to find new markers that can be used in the detection of ovarian cancer to improve early diagnosis and survival rates of women with ovarian cancer. Our study focuses on presenting the currently used diagnostic markers and the latest selected immunological and molecular parameters being currently investigated for their potential use in the development of new diagnostic and therapeutic strategies.

show abstract

“…24 Recent studies also revealed that serum HE4 was a useful diagnostic marker for other types of cancer, such as lung cancer 25,26 and endometrial cancer. 27,28 In addition, serum HE4 increases in HF patients, and higher HE4 predicts worse outcomes in HF patients. 29 Notably, previous studies showed that both serum tumor markers and their pleural fluid counterparts helped diagnose MPE, 13 and the diagnostic accuracy of pleural fluid tumor markers was higher than their serum counterparts.…”

Section: Introductionmentioning

confidence: 99%

Value of human epididymis secretory protein 4 in differentiating malignant from benign pleural effusion: an analysis of two cohorts

Yang,

Niu,

Wen

et al. 2023

Ther Adv Respir Dis

View full text Add to dashboard Cite

Background: Lung cancer is the most common cause of malignant pleural effusion (MPE). Serum human epididymis secretory protein 4 (HE4) is a useful diagnostic marker for lung cancer. Objective: This study aimed to evaluate the diagnostic accuracy of pleural fluid HE4 for MPE. Design: A prospective, double-blind diagnostic test accuracy study. Methods: Patients with undiagnosed pleural effusion were enrolled in two cohorts (Hohhot and Changshu). Electrochemiluminescence immunoassay was used to detect pleural fluid HE4. The diagnostic accuracy of HE4 was evaluated by a receiver operating characteristic (ROC) curve, and the net benefit of HE4 was assessed by a decision curve analysis (DCA). Results: A total of 66 MPEs and 86 benign pleural effusions (BPEs) were enrolled in the Hohhot cohort. In the Changshu cohort, 26 MPEs and 32 BPEs were enrolled. In both cohorts, MPEs had significantly higher pleural fluid HE4 than BPEs. The area under the ROC curve (AUC) of HE4 was 0.73 (95% CI: 0.64–0.81) in the Hohhot cohort and 0.79 (95% CI: 0.67–0.91) in the Changshu cohort. At a threshold of 1300 pmol/L, HE4 had sensitivities of 0.44 (95% CI: 0.33–0.56) in the Hohhot cohort and 0.54 (95% CI: 0.35–0.73) in the Changshu cohort. The corresponding specificities were 0.90 (95% CI: 0.83–0.95) in the Hohhot cohort and 0.94 (95% CI: 0.84–1.00) in the Changshu cohort. In subgroup analyses, HE4 had an AUC (95% CI) of 0.78 (0.71–0.85) in exudates and an AUC of 0.69 (0.57–0.81) in patients with negative effusion cytology. The DCA revealed that HE4 determination had a net benefit in both cohorts. Conclusion: Pleural fluid HE4 has moderate diagnostic accuracy for MPE and has net benefit in pleural effusion patients with unknown etiology.

show abstract

Prognostic values of human epididymis protein 4 expression in patients with endometrial cancer: A systematic review and meta‐analysis

Cited by 6 publications

References 47 publications

Sensitivity and Specificity of Selected Biomarkers and Their Combinations in the Diagnosis of Ovarian Cancer

Sensitivity and Specificity of Selected Biomarkers and Their Combinations in the Diagnosis of Ovarian Cancer

Evaluation of the Potential Diagnostic Utility of the Determination of Selected Immunological and Molecular Parameters in Patients with Ovarian Cancer

Value of human epididymis secretory protein 4 in differentiating malignant from benign pleural effusion: an analysis of two cohorts

Contact Info

Product

Resources

About